Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Allylestrenol

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,786Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sun Pharma Looks To Rise In US With $10 Billion Organon Buy
    Sun Pharma Looks To Rise In US With $10 Billion Organon Buy

    18 Jan 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-looks-to-rise-inus-with-10-billion-organon-buy/articleshow/126660959.cms

    ECONOMICTIMES
    18 Jan 2026
    Share Share
    Organon Announces FDA Approval of sNDA Extending Use of Nexplanon
    Organon Announces FDA Approval of sNDA Extending Use of Nexplanon

    17 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-17/organon-announces-us-food-and-drug-administration-approval-of-supplemental-new-drug-application-exte

    PHARMIWEB
    17 Jan 2026
    Share Share
    Organon To Present At Piper Sandler Healthcare Conference
    Organon To Present At Piper Sandler Healthcare Conference

    25 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125341955/en/Organon-To-Present-at-the-Piper-Sandler-37th-Annual-Healthcare-Conference

    BUSINESSWIRE
    25 Nov 2025
    Share Share
    FDA Approves POHERDY® as First PERJETA Biosimilar
    FDA Approves POHERDY® as First PERJETA Biosimilar

    17 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251117955804/en/Henlius-and-Organon-Announce-US-FDA-Approval-of-POHERDY-pertuzumab-dpzb-the-First-PERJETA-pertuzumab-Biosimilar-in-the-US

    BUSINESSWIRE
    17 Nov 2025
    Share Share
    Poherdy, First Biosimilar To Roche's Perjeta, Scores FDA Nod
    Poherdy, First Biosimilar To Roche's Perjeta, Scores FDA Nod

    14 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/organon-and-henlius-poherdy-first-biosimilar-roches-perjeta-approved-fda

    FIERCE PHARMA
    14 Nov 2025
    Share Share
    Organon Releases Q3 2025 Results
    Organon Releases Q3 2025 Results

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110058374/en/Organon-Reports-Results-for-the-Third-Quarter-Ended-September-30-2025

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.